Skip to main content

Table 1 Strategies for safer CAR-T therapy

From: Development of molecular and pharmacological switches for chimeric antigen receptor T cells

Strategy Mechanism
Suicide gene Incorporation of suicide genes (iCasp9, EGFRt) [3, 4]
Combinational targeted activation Two antigen recognitions are required to fully activate CAR-T cells [5]
Inhibitory CAR-T cells Recognition of normal cell induces inhibition of CAR-T cell activity [6]
CAR modification Modification of CAR molecules to identify constructs with less cytokine production activity but with preserved anti-tumor function [7]
On/off switch for CAR-T cell Dasatinib serves as an on/off switch for CAR-T cells [8]